Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation: one-year dynamic observation

Ilona Hartmane (Coresponding Author), Iveta Ivdra, Ingmārs Mikažāns, Vanda Bondare-Ansberga

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)

Abstract

Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.
Original languageEnglish
Pages (from-to)357-363
Number of pages7
JournalProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Volume75
Issue number5
DOIs
Publication statusPublished - 1 Oct 2021

Keywords*

  • TNF-a inhibitors
  • adalimumab
  • parameters of cellular and humoral immunity
  • T cells

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation: one-year dynamic observation'. Together they form a unique fingerprint.

Cite this